Seok Hyeri, Kang Cheol-In, Huh Kyungmin, Cho Sun Young, Ha Young Eun, Chung Doo Ryeon, Peck Kyong Ran
Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul, Republic of Korea.
Microb Drug Resist. 2018 Nov;24(9):1412-1416. doi: 10.1089/mdr.2017.0416. Epub 2018 Mar 22.
Fluoroquinolones are antibiotics commonly used in the treatment of infections caused by Streptococcus pneumoniae. However, rates of fluoroquinolone resistance are increasing with their frequent use. We designed this study to verify current fluoroquinolone resistance rates and risk factors for community-onset pneumococcal pneumonia.
A retrospective case-control study was conducted in a tertiary referral hospital. The study population comprised patients admitted for pneumococcal pneumonia between January 2011 and May 2017. The case group included community-onset pneumonia caused by levofloxacin-nonsusceptible S. pneumoniae. The control group consisted of two patients with levofloxacin-susceptible S. pneumoniae who were admitted around the same time as each case.
A total of 198 pneumococcal pneumonia cases were identified during the study period. Twenty-five levofloxacin-resistant S. pneumoniae cases and 3 levofloxacin-intermediate S. pneumoniae cases were included in the case group (nonsusceptibility rate = 14.1%). Multivariate analysis showed that healthcare-associated factors (odds ratio [OR] 4.78, 95% confidence interval [CI] 1.39-16.43, p = 0.013), bronchopulmonary disease (OR 3.79, 95% CI 1.07-13.40, p = 0.039), cerebrovascular disease (OR 6.08, 95% CI 1.24-29.75, p = 0.026), and exposure to fluoroquinolones within the previous 3 months (OR 5.89, 95% CI 1.21-28.68, p = 0.028) were associated with nonsusceptibility to levofloxacin.
Independent risk factors for levofloxacin-nonsusceptible pneumococcal pneumonia were recent hospitalization, bronchopulmonary disease, cerebrovascular disease, and prior antibiotic use within 3 months. Careful selection of empirical antibiotics is thus needed in at-risk patients. Similarly, efforts to prevent the interpersonal spread of drug-resistant pathogens in long-term care facilities and to restrict unnecessary fluoroquinolone prescriptions are important.
氟喹诺酮类药物是治疗肺炎链球菌感染常用的抗生素。然而,随着其频繁使用,氟喹诺酮类耐药率正在上升。我们开展本研究以核实社区获得性肺炎链球菌肺炎当前的氟喹诺酮类耐药率及危险因素。
在一家三级转诊医院进行一项回顾性病例对照研究。研究人群包括2011年1月至2017年5月因肺炎链球菌肺炎入院的患者。病例组包括由左氧氟沙星不敏感肺炎链球菌引起的社区获得性肺炎。对照组由两名与每个病例同时入院的左氧氟沙星敏感肺炎链球菌患者组成。
研究期间共确定198例肺炎链球菌肺炎病例。病例组包括25例左氧氟沙星耐药肺炎链球菌病例和3例左氧氟沙星中介肺炎链球菌病例(不敏感率=14.1%)。多因素分析显示,医疗相关因素(比值比[OR]4.78,95%置信区间[CI]1.39 - 16.43,p = 0.013)、支气管肺部疾病(OR 3.79,95%CI 1.07 - 13.40,p = 0.039)、脑血管疾病(OR 6.08,95%CI 1.24 - 29.75,p = 0.026)以及在过去3个月内接触过氟喹诺酮类药物(OR 5.89,95%CI 1.21 - 28.68,p = 0.028)与对左氧氟沙星不敏感相关。
左氧氟沙星不敏感肺炎链球菌肺炎的独立危险因素为近期住院、支气管肺部疾病、脑血管疾病以及3个月内曾使用抗生素。因此,对于高危患者需要谨慎选择经验性抗生素。同样,努力防止耐药病原体在长期护理机构中的人际传播以及限制不必要的氟喹诺酮类药物处方也很重要。